Previous applications of TUS were limited, as they were imprecise and too weak to target areas deeper in the brain. Parkinson ...

Researchers have designed a peptide that prevents the deadly misfolding of alpha-synuclein, the protein behind Parkinson’s ...

B55alpha, that controls both the cleanup of damaged mitochondria and the creation of new ones. In Parkinson’s disease models, ...

If you have been following AbbVie (ABBV), the company’s latest move might sway your decision on whether to stick with or jump ...

The submission is based on results from the TEMPO clinical development program that evaluated the efficacy, safety and tolerability of tavapadon across a broad Parkinson's disease ...

Neurocrine Biosciences Inc on Monday launched its add-on treatment for patients with Parkinson's disease nearly five months after Food and Drug Administration's approval, as the COVID-19 pandemic ...

A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical ...

The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.

IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: ...

A drug first developed in the 1950s for Parkinson’s disease may be an unexpected ally in the global fight against tuberculosis, according to new research from the University of British Columbia (UBC).

Annovis Bio, Inc. (NYSE: ANVS) shares gained Thursday. The Malvern, Pa.-based company, a late-stage clinical drug platform firm pioneering transformative therapies for neurodegenerative diseases such ...